Relay Therapeutics, Inc. (RLAY) stock
Close on Nov 12, 2026Market cap $3.96BP/E –Yield –
Relay Therapeutics, Inc. grew revenue 23.9% to $10.35M over the twelve months to Sep 30, 2026. Free cash flow was -$235.87M. At the latest close the market valued the company at $3.96B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $3.96B
- P/E ratio
- –
- Price to sales
- 382.81
- Price to book
- 4.84
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $10.35M
- Net income
- -$293.63M
- EPS, diluted
- -$1.51
- Free cash flow
- -$235.87M
- Book value per share
- $3.74
- Diluted shares
- 219M
Trading
- Next earnings
- Feb 25, 2027 (estimated, after the close)
- Previous close
- $19.72
- Open
- $19.45
- Day's range
- $18.05 – $19.50
- Volume
- 2,768,503
- Average volume (20 days)
- 2,606,915
- Index membership
- Russell 2000 (since Sep 2020), Russell 3000 (since Nov 2020)
- Beta (5 years)
- 1.96
- 52-week range
- $5.95 – $21.27
- RSI (14 days)
- 56.9
- Volatility (1 year)
- 65.2%
- Relative volume
- 0.69×
- WACC
- 14.7%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | RLAY | S&P 500 | Difference | RLAY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +0.6% | -2.7% | +3.3 pts | ||
| 3 months | -9.9% | -1.7% | −8.2 pts | ||
| Year to date | +113.7% | +11.9% | +101.8 pts | ||
| 1 year | +193.0% | +12.0% | +181.0 pts | ||
| 3 years | +136.0% | +78.2% | +57.9 pts | +33.1% | +21.2% |
| 5 years | -48.7% | +73.2% | −121.9 pts | -12.5% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Relay Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Update
- Results
About Relay Therapeutics
Biological Products, (No Diagnostic Substances)
Relay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule drug candidates. The firm concentrates its efforts on precision oncology and genetically defined diseases through targeted therapies designed to address validated biological mechanisms. Rather than offering commercialized medical products, its clinical pipeline includes experimental drug programs and therapeutic opportunities being investigated for targeted patient groups.
Company profile, executives and historyRelay Therapeutics stock: common questions
What is Relay Therapeutics's stock price?
RLAY closed at $18.08 on Nov 12, 2026, down 8.32% on the day. Over the past 52 weeks it traded between $5.95 and $21.27.
What is Relay Therapeutics's market cap?
Relay Therapeutics was worth $3.96B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is RLAY's P/E ratio?
Relay Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.51), so it has no meaningful P/E ratio.
How much revenue does Relay Therapeutics make?
Relay Therapeutics reported revenue of $10.35M for the twelve months to Sep 30, 2026, up 23.9% from a year earlier.
Does Relay Therapeutics pay a dividend?
No. Relay Therapeutics has not paid a cash dividend over the last twelve months.
When does Relay Therapeutics report earnings next?
Relay Therapeutics is expected to report Q4 FY2026 results on Feb 25, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has RLAY stock performed over the past year?
Including dividends, RLAY returned +193.0% over the past year, against +12.0% for the S&P 500.
How many RLAY shares are sold short?
44M shares were sold short at the latest FINRA report, 26.35% of the float, or 20.7 days of average trading volume.
Who are Relay Therapeutics's competitors?
Companies most similar to Relay Therapeutics by business, industry and size include ELOX, CRIS, CRBU, MOLN, PRLD.
See a number that looks wrong?